Aquestive Therapeutics, Inc.
Anaphylm
treatment of Type I allergic reactions, including anaphylaxis
Resolved
67days ago
Catalyst readout · May 1, 2026
What's at stake
A key catalyst for Anaphylm (treatment of Type I allergic reactions, including anaphylaxis) is expected May 1, 2026.
Primary source
· SEC 8-K
verified 16h ago
“Type A Meeting with FDA March 26, 2026”